Antimicrobial dosing should account for patient (weight, renal function), antimicrobial (pharmacokinetics, pharmacodynamics, toxicity) and disease state.

For allergies, refer beta-lactam allergy guideline on IDMP.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For additional drugs, doses, and details, visit https://idmp.ucsf.edu/antimicrobial-dosing-guidelines

Approved by the Antimicrobial Subcommittee and the Pharmacy and Therapeutics Committee June 2022.

Restricted antimicrobial orders will NOT be processed without appropriate prior authorization from the ID consultant.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

Restricted agents at respective sites.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.

For questions related to patients actively followed by the ID Consult Service, refer to Voalte.